Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-002), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.
Alto crecimiento
Los ingresos de la empresa han crecido de manera constante durante los últimos tres años, con un promedio interanual del 2000.46%.
Infravalorada
El PE más reciente de la empresa es -10.25, en un rango percentil bajo de 3 años.
Venta institucional
Las tenencias institucionales más recientes son 73.67M acciones, lo que supone una reducción del 7.37% con respecto al trimestre anterior.
En posesión de John Hussman
El inversor estrella John Hussman posee 87.12K acciones de este valor.
Mayor actividad del mercado
La empresa está generando mayor interés entre los inversores, con una relación de rotación de 20 días del 0.15.